GreenLight Biosciences, Inc.
200 Boston Avenue
Suite 1000
Medford
Massachusetts
02155
United States
Tel: 617-716-7777
Website: http://www.greenlightbiosciences.com/
About GreenLight Biosciences, Inc.
GreenLight Biosciences is an integrated life sciences company with a cutting-edge platform to deliver higher-quality RNA at a lower cost and more quickly than was ever before possible.
GreenLight develops RNA products and collaborates with industry leaders to advance vaccine development, pandemic preparation, crop management, plant protection and support the health of bees and other pollinators. The GreenLight team values diversity, inclusion, and equality and promises to use collaboration to remain scientifically imaginative and passionately focused on making a difference in the world.
GreenLight is currently innovating in both the agriculture and life sciences industries. We aim to bring safe, effective solutions to market that are driven by rigorous scientific innovation. With your skills, you can help us get there.
CEO Andrey Zarur on the personal reason he founded GreenLight Biosciences
52 articles about GreenLight Biosciences, Inc.
-
GreenLight Biosciences Holdings, PBC (GRNA) enters into multitarget licensing agreement with Serum Institute of India to develop and commercialize messenger RNA products for emerging markets globally
3/14/2022
GreenLight Biosciences Holdings PBC today announced a licensing agreement with Serum Institute of India, Pvt, Ltd., aimed at accelerating accessibility to messenger RNA products in emerging markets globally.
-
GreenLight Biosciences begins trading today as Nasdaq: GRNA on the closing of its business combination with Environmental Impact Acquisition Corp.
2/3/2022
GreenLight Biosciences ("GreenLight"), a biotechnology company dedicated to making ribonucleic acid (RNA) products affordable and accessible for human health and agriculture, and Environmental Impact Acquisition Corp. (Nasdaq: ENVI) ("ENVI"), a special purpose acquisition company, yesterday announced the closing of their previously announced business combination.
-
ENVI and GreenLight Biosciences Announce Filing of Definitive Proxy Statement/Prospectus and the February 1st, 2022 Special Meeting to Approve Proposed Business Combination
1/14/2022
Environmental Impact Acquisition Corporation announced today that ENVI's definitive proxy statement/prospectus (the "Proxy Statement") relating to the previously announced business combination with GreenLight Biosciences, Inc.
-
GreenLight (ENVI) and IAVI begin work on Omicron variant-adapted COVID-19 vaccine candidate
12/3/2021
GreenLight Biosciences and IAVI, a nonprofit scientific research organization, announced work on a messenger RNA vaccine candidate to tackle the COVID-19 Omicron variant.
-
GreenLight Biosciences and Samsung Biologics announce collaboration to build capacity for messenger RNA Vaccine Manufacturing
11/24/2021
GreenLight Biosciences and Samsung Biologics announced a partnership agreement in which Samsung Biologics will manufacture GreenLight's messenger RNA COVID-19 vaccine candidate at commercial scale.
-
Serum Life Sciences invests in RNA biotech GreenLight by joining expanded financing for Environmental Impact Acquisition Corp.
11/23/2021
GreenLight Biosciences Inc., an RNA-focused biotech, and Environmental Impact Acquisition Corp. announced an expansion of its PIPE financing to an aggregate $124 million in gross proceeds.
-
Many mergers took place in 2021. Here’s a look at some of the hottest life sciences SPAC merger announcements so far in 2021. Many mergers took place in 2021, -
Greenlight Biosciences (ENVI) Adds Two World-Renowned Scientists To Its Scientific Advisory Board
11/4/2021
GreenLight Biosciences is delighted to announce the appointment of Professor Diane E. Griffin, MD, PhD, and Emmanuel Hanon, DVM, PhD, to its Human Health Scientific Advisory Board.
-
While some may wonder about the commercial future of these late-to-the-market solutions, the developers themselves are taking a long view. -
Here’s a look at a few of the industry expansions that have been announced so far this month. -
GreenLight Biosciences opens RNA production facility for the next generation of agricultural products
9/23/2021
GreenLight Biosciences, Inc., a biotechnology company focused on RNA research, design, and manufacturing for human, animal, and plant health, announced the opening of its manufacturing plant in Rochester, New York, Bloomberg reports.
-
GreenLight Biosciences Announces the Appointment of Jennifer Raymond As SVP, CMC and Manufacturing
9/16/2021
GreenLight Biosciences, Inc. announced the appointment of Jennifer Raymond as SVP, CMC Manufacturing today.
-
Money on the Move: August 4 – 10
8/11/2021
Check out where the money went in the life sciences industry this week. -
Messenger RNA has become the life sciences hero of the decade. The lynchpin in the fight against COVID-19, companies are taking mRNA technology to new heights. -
GreenLight Biosciences Acquires Bayer's topical RNA Intellectual Property portfolio
5/20/2021
GreenLight Biosciences today announced that they have acquired rights to portions of Bayer's topical RNA Intellectual Property portfolio. These assets include bee health capabilities to protect against Varroa mites, a major threat to honeybees.
-
GreenLight Biosciences Welcomes Amin Khan As Chief Scientific Officer, Human Health
4/28/2021
GreenLight Biosciences, Inc., a biotechnology company focused on RNA research, design, and manufacturing for human, animal, and plant health, today announced the appointment of Amin Khan as the company's Chief Scientific Officer, Human Health.
-
GreenLight Biosciences Publishes Blueprint to Vaccinate the World
3/26/2021
GreenLight Biosciences today published its Blueprint to Vaccinate the World. This plan lays out how the world can quickly end the Covid pandemic by investing in a global network of seven vaccine manufacturing plants.
-
GreenLight Biosciences Welcomes Mark Singleton As Lead For Plant Health Innovation
3/3/2021
GreenLight Biosciences, Inc., a biotechnology company focused on RNA research, design and manufacturing for human, animal and plant health, announced the appointment of Mark Singleton as the company's Senior Vice President of Technology and External Innovation.
-
Greenlight Biosciences Welcomes Thomas Crampton as Senior Vice President for Corporate Affairs
1/27/2021
GreenLight Biosciences, Inc., a biotechnology company focused on RNA research, design and manufacturing for human, animal and plant health, announced the appointment of Thomas Crampton as the company's Senior Vice President for Corporate Affairs.
-
Manufacturing capacity is often decried as a major bottleneck in administering COVID-19 vaccines to a global population of 7.8 billion. For mRNA vaccines, the bottleneck is the availability of raw materials, not bioreactors.